The average drug costs $2.3 billion to bring to market. Roughly 30% of completed trials never publicly report their results. Kalshi’s answer: turn the science itself into a tradeable contract. $128,000 changed hands on day one. Critics say it also creates a direct financial incentive to leak confidential trial data.
Kalshi’s biotech prediction markets launched in partnership with AppliedXL, a public intelligence firm that monitors and predicts clinical trial outcomes. The pilot suite covers 13 initial contracts letting traders bet directly on Phase 3 trial results and full FDA approval decisions — including whether regulators will approve medicines made by companies like Sanofi and Gilead Sciences. “The odds that a drug will succeed are among the most valuable numbers in the economy, and among the least visible,” Kalshi said in a joint whitepaper published alongside the launch. CFTC Chair Michael Selig, whose agency regulates prediction markets, has separately touted drug-trial contracts as a way for sick people to hedge their future treatment costs. By contrast, critics warn the structure creates a direct financial incentive to trade on nonpublic clinical information — potentially influencing the very trials the contracts are designed to price.
What’s Happening & Why It Matters
The Information Gap Kalshi Says It’s Closing
Kalshi’s biotech prediction markets target a specific and well-documented transparency problem in pharmaceutical research. As of the FDA’s April 2026 figures, roughly 30% of trials required to report their results had posted none. Banks, expert networks, and pharmaceutical companies all produce internal estimates of a drug’s likelihood of success — but those estimates stay behind closed doors. Each Kalshi contract specifies a named public document as its resolution source: the registered primary endpoint on ClinicalTrials.gov, the FDA approval letter, or the advisory committee vote record — meaning outcomes are verified against an official public record rather than a private judgment call.
By contrast, Kalshi is deliberately starting narrow. Initially, the platform will only allow people to bet on Phase 3 trial outcomes run by established biopharma companies and full FDA approval decisions — not early-stage trials or conditional approvals. Kalshi said those later-stage results have more clear-cut outcomes than exploratory early trials, which tend to carry ambiguous endpoints unsuited to a binary bet.
$128,000 on Day One and the Insider Trading Problem
Kalshi’s biotech prediction markets attracted immediate trading volume: more than $100,000 in bets within hours of launch, reaching $128,401 in Kalshi’s “medicine” market category by mid-afternoon on launch day. By contrast, that volume is small relative to Kalshi’s business — in the last week of June, the platform hosted just $3.6 million in trading across all science and technology topics combined, compared with $5.4 billion in sports contracts during the same period, according to Dune Analytics data.
The core risk critics identify is structural. People with privileged knowledge — company employees, clinical investigators, doctors, or nurses involved in a trial — could trade on confidential information before it is public, distorting thinly traded markets or creating incentives to leak results early. Kalshi says it plans to use employment verification to monitor for insider trading, similar to how it handles other contracts tied to corporate data. Additionally, critics warn the markets could influence patients directly — some may decide to withdraw from or stay in a study based on betting odds rather than medical advice from their own physicians.
The Consultation Process
Kalshi’s biotech prediction markets followed a specific and deliberately cautious development process, according to the company. Kalshi says it spent months consulting physicians, pharmaceutical researchers, bioethicists, and other experts before launching its biotech initiative. Those consultations included Alpheus Bingham, a former Eli Lilly scientist who helped build an internal prediction market in the early 2000s to forecast the success of various drug and research projects at the company — giving Kalshi direct institutional experience with a comparable, if privately scoped, prior attempt at the exact concept.
Alongside the launch, Kalshi and AppliedXL published a joint whitepaper — Biopharma’s Public Probability: The State and Future of Prediction Markets in Drug Development — drawing on interviews with clinicians, academics, biopharma R&D professionals, bioethicists, and investors. The paper examines both the opportunities and the specific standards required for the markets to function reliably without corrupting the science they aim to price.
A Single Isolated Question
Kalshi’s biotech prediction markets offer investors a distinct instrument compared to standard equity trading. Public equities force a position on an entire business at once — management, cash position, pipeline, and macro conditions all together. An investor can be right about the underlying science or the regulatory outcome specifically and still watch the stock move the other way, because dozens of unrelated corporate factors move share prices simultaneously. The new contracts isolate the single question: owning the stock is still owning the whole company, while a Kalshi contract prices the science or the regulatory outcome on its own terms, independent of everything else happening at that company.
As TF covered in its Kalshi New York gambling ruling article, Kalshi is simultaneously navigating a fragmented state-by-state legal battle over whether its core sports contracts constitute regulated financial products or unlicensed gambling. Additionally, Bloomberg separately reported Kalshi is evaluating whether to offer wagers on flight-cancellation rates at specific airports — part of a consistent pattern of expanding into new categories of real-world binary events well beyond the platform’s original political and sports focus.
TF Summary: What’s Next
The pilot programme covers 13 initial contracts focused on Phase 3 trials and FDA approval decisions for established biopharma companies. Kalshi says it hopes to expand into early-stage trials and conditional approvals “if its initial markets work smoothly.” Employment verification for insider trading monitoring is the primary safeguard mechanism disclosed publicly. No regulatory response from the FDA itself has been reported regarding the new contracts.
MY FORECAST: Kalshi’s biotech prediction markets will generate useful public probability signals for well-covered, large-cap pharmaceutical trials — the kind of information asymmetry Kalshi is targeting is real, and aggregating dispersed expert opinion into a single tradeable number has worked reasonably well in other prediction market categories. By contrast, the insider trading risk is the more serious unresolved question, and employment verification alone will not catch every leak — clinical trial sites involve hundreds of staff, contractors, and data monitoring board members who fall outside any single company’s employment records. Expect the first documented insider trading controversy in the specific market category within 12 months, likely triggering either a Kalshi-imposed trading halt on the affected contract or renewed CFTC scrutiny of the entire biotech vertical — testing whether Selig’s stated enthusiasm for the markets survives contact with a leak.
Related Stories
- Polymarket Paid Creators to Fake Winning Bets in Viral Videos
- New York Can Restrict Prediction Market Gambling, Federal Judge Rules
- Meta Is Building ‘Arena’ — a Prediction Market App to Challenge Polymarket and Kalshi